In the spotlight
Mechanisms of inflammation and tissue remodelling in chronic diseases
Home / Our therapy areas / Respiratory & Immunology
We are focused on chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), as well as immune-driven diseases such as lupus. We follow the science to address tough and complex, unsolved problems - targeting the underlying biology and developing effective new drug modalities and combinations with the ultimate ambition of achieving disease modification and clinical remission.
Click on the links below to learn more about our focus areas:
It is an exciting time to work in Respiratory & Immunology, as we continue to work towards transforming care for some of the most debilitating and chronic respiratory and immune-mediated diseases. By targeting the underlying biology and applying a precision medicine approach from the start of discovering medicines, we aim to move beyond symptom control to disease modification, remission and one day, cure.
Our Respiratory & Immunology therapy area is driven by innovation and our commitment to make a real-life difference in patient’s lives. That difference starts with you. IDEA Pharma ranked us #1 on their Invention Index and #2 on their Innovation Index and we are recognised as a top employer in 2021/2022 by Forbes, Financial Times and Biospace. We need people like you who share our passion for science and determination to meet patients’ needs around the world.
Visit our careers website and:
Through collaboration and partnerships, we can accelerate positive change and outcomes for patients. We work with leading research and academic institutions, public health authorities, patient groups and professional organisations across respiratory and immune-mediated diseases.
As part of our commitment to transform respiratory care for all patients, we are a founding partner of the International Respiratory Coalition. The Coalition aims to support the transformation of post-pandemic respiratory healthcare and reduce deaths from respiratory disease by one-third globally by 2030. This goal, which aligns with the fast-approaching deadline set for the United Nation’s Sustainable Development Goals1, will be delivered through the creation or update of national respiratory strategies which accelerate and scale adoption of good practice care models.
The world can no longer afford to overlook COPD.2 That is why we are working with leading respiratory groups and patient allies from around the world to make this disease a public health priority. This cross-industry and multi partnered campaign has one critical goal: to increase the awareness and understanding of COPD among policymakers and healthcare systems. Together we are aiming to unlock policy change barriers that can optimise COPD care.
While important progress has been made in our understanding of severe asthma, there is still significant unmet need and too many people do not receive the treatment and care they deserve.3,4 By increasing awareness of the new evidence on the continuing impact of severe asthma on patients’ lives and linking these challenges with tangible good practice case studies solutions, this campaign aims to drive urgency among policymakers and healthcare professionals to help address the barriers that underpin suboptimal care.
Our mission is to eliminate asthma attacks and enable people with asthma to live life to the fullest. Through increasing awareness and motivating systems and clinical practice to implement evidence-based guidelines for optimal asthma care, the Break Over-Reliance campaign seeks to break the cycle of over-reliance on SABA inhalers for asthma treatment.
zafirlukast
glycopyrronium/formoterol fumarate
budesonide/glycopyrronium/formoterol fumarate
terbutaline
terbutaline in a dry powder inhaler
roflumilast
aclidinium/formoterol
aclidinium, a LAMA
benralizumab
Oxis Turbuhaler
budesonide inhalation suspension
budesonide
budesonide
anifrolumab
budesonide/formoterol
budesonide/formoterol
tezepelumab
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.
Phase I
Phase II
Phase III
LCM Projects
1. United Nations. Sustainable Development Goals. Available at: http://www.un.org/sustainabledevelopment/sustainable-development-goals/. [Last accessed: August 2022].
2. World Health Organization. COPD Factsheet. Available at: http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). [Last accessed: August 2022].
3. Chen S, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34:2075–2088
4. Peters SP, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006: 100 (7): 1139-51.
Veeva ID: Z4-51416
Date of preparation: December 2022